Briefing
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial
Final analysis, median follow-up 42.2 months. Of 118 MRD-evaluable patients, 96 (81%, 95% CI 73-88) reached MRD <10^-5 and 84 (71%, 62-79) reached MRD-SURE and stopped therapy. 36-month PFS: 88% (no HRCA), 79% (1 HRCA), 50% (2+ HRCAs). Among 84 who stopped therapy, 24-month cumulative incidence of progression from cessation was 9%, 9%, and 47% by HRCA group. MRD-adapted cessation was feasible in 0-1 HRCA disease; patients with 2+ HRCAs had higher progression after stopping.
- Design: paper
- n: 123
- Assay: NGS MRD, 10^-5 (MRD-evaluable n=118 of 123)